Company: VRCA
Filing Date: 2025-04-30
Form Type: DEFR14A
Source: 0001193125-25-105562
Chunk: 46

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-04-30
Form: DEFR14A
Chunk 46
---
 VA 22902. |

| (2) | This information has been obtained, in part, from a Schedule 13G filed on February 14, 2025 by entities and individuals associated with Armistice Capital. LLC (“Armistice”). Consists of (a) 9,134,817 shares of common stock and (b) a total of 38,888 shares of common stock issuable upon exercise of warrants (the “Armistice Warrants”) held by Armistice, which due to the Armistice Beneficial Ownership Limitation (as defined below) is the maximum number of shares that can be issued upon the exercise of the Armistice Warrants within 60 days of April 1, 2025. Pursuant to the terms of the Armistice Warrants, the holder of such Armistice Warrants does not have the right to exercise any portion of the Armistice Warrants, to the extent that, after giving effect to the attempted exercise set forth in a notice of exercise, such holder, together with such holder’s affiliates and any other person whose beneficial ownership of common stock would be aggregated with such holder’s for the purposes of Section 13(d) of the Exchange Act and the applicable regulations of SEC, including any “group” of which such holder is a member, would beneficially own a number of shares of common stock in excess of the Armistice Beneficial Ownership Limitation. As of April 1, 2025, the “Armistice Beneficial Ownership Limitation” is 9.99% of the shares of common stock then issued and outstanding. Armistice is the investment manager of Armistice Capital Master Fund Ltd. (the “Master Fund”), the direct holder of the shares, and pursuant to an Investment Management Agreement, Armistice exercises voting and investment power over the securities held by the Master Fund and thus may be deemed to beneficially own the securities held by the Master Fund. Steven Boyd, as the managing member of Armistice, may be deemed to beneficially own the securities held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice. The address of Armistice is 510 Madison Avenue, 7th Floor, New York, NY 10022. |

| (3) | This information has been obtained from a Schedule 13